Navigation Links
Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:6/16/2009

to share this promising data from our current U.S.

Cotara clinical trial with experts at this prestigious conference, and we look forward to reporting further data from this study and from our Phase II trial in patients with recurrent GBM."

More than 65 patients with recurrent GBM have received Cotara in the current and previous clinical studies. Localization and accumulation of the drug to the tumor have been excellent and longer-term survivors (greater than one year from the time of Cotara treatment) have been observed in all of the trials, with some GBM patients from early clinical studies now alive more than 8.5 years after treatment with Cotara. Expected survival for patients with GBM is approximately six months from the time of disease recurrence.

The Cotara data will be presented today at the 2009 Society for Nuclear Medicine (SNM) Annual Meeting in Toronto, Canada, in a session scheduled from 12:30 PM to 2:00 PM EDT in Room 701B.

Abstract No: 150240; Publication No: 445: S. Shen(1), R. Lustig(2), K. Judy(2), W. Shapiro(3), K. Spicer(4), S. Patel(4), J. Fiveash(1), J. Lai(5), J. Shan(5), "Dosimetry of phase I interstitial 131I-chTNT-1/B MAb (Cotara) for the treatment of recurrent glioma."

(1)U Alabama, Birmingham, AL; (2)U Penn, Philadelphia, PA; (3)BNI St. Joseph's MedCtr, Phoenix, AR; (4)Med U S Carolina, Charleston, SC; (5)Peregrine Pharma Inc, Tustin, CA

About Cotara(R)

Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to the DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara's targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... highlights for the quarter ended June 30, 2014 on ... close. Regulus will host a conference ... 5:00 pm Eastern Daylight Time to discuss its second ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... and NYSE: SNY) today announced that the Companies intend ... rare pediatric disease priority review voucher in connection with ... priority review voucher entitles the holder to designate a ... 6-month review from the filing date instead of the ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... July 30, 2014  Decision Resources Group finds ... directors in the United States ... market penetration will be the level of savings ... the expected lower cost to patients. Payers plan ... meet their pricing expectations in order to encourage ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Senomyx, Inc.,(Nasdaq: SNMX ) will release its ... before the opening of the U.S. financial,markets. The Company ... Internet,broadcast that will provide a business update and a ... at 11:00 a.m. Eastern Time (8:00 a.m.,Pacific Time)., ...
... Oct. 20 GeoVax Labs, Inc. (OTC,Bulletin Board: ... for diseases caused by HIV-1 (Human Immunodeficiency Virus),and ... both DNA and,MVA components of its AIDS vaccine ... use in the upcoming Phase 2a human clinical ...
... with Industry to Educate,Promote PRV Program-, WASHINGTON, ... today announced its support of the US Food ... Industry on Priority,Review Vouchers. The Priority Review Voucher ... the development of drugs and vaccines for,neglected tropical ...
Cached Biology Technology:SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008 2GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial 2GeoVax's DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial 3FDA Issues Draft Guidance on Priority Review Vouchers 2
(Date:7/30/2014)... University is paving the way for a breakthrough ... military troops exposed to poisonous chemicalsparticularly those in ... in the current issue of the journal ... which are compounds commonly used in pesticides and ... NYU School of Engineering Associate Professor of Chemical ...
(Date:7/30/2014)... uses reversible epigenetic processes to regulate its genes, and ... a picture of the genome regulation taking place in ... Genome Biology and illustrates how the truffle ... genes,. The authors say this may shed light on ... Black truffles (Tuber melanosporum), also known as Prigord truffles, ...
(Date:7/30/2014)... the Red Queen in Lewis Carroll,s Through the ... and National University of Singapore improved a 35-year-old ... over decades to millions of years. , The ... competition, incorporates the "Red Queen Effect," an evolutionary ... 1970s, which suggests that organisms must constantly increase ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2How black truffles deal with the jumpers in their genome 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... October 23, 2013 A promising technique for treating ... may lead to new treatments to prevent blindness, according to ... Jolla, California. The studies involved controlling the actions ... to be "junk" but are now known to fine-tune gene ...
... have found out which molecular mechanisms decide about the ... for the import of proteins into specific cell components, ... receptor remains active or is broken down after the ... regulation of the protein import into peroxisomes has been ...
... simply cannot do without lasers. We use them to print ... car components, survey roads, monitor our bloodstream, and even remove ... for Applied Solid State Physics IAF in Freiburg have developed ... a particular type of infrared laser forms the ...
Cached Biology News:New eye treatment effective in laboratory tests 2New eye treatment effective in laboratory tests 3New eye treatment effective in laboratory tests 4The yin and yang in the life of proteins 2Lasers offer an automated way to test drinking water 2Lasers offer an automated way to test drinking water 3
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Mouse monoclonal antibody raised against a partial recombinant TPR. NCBI Entrez Gene ID = TPR...
... Each kit contains sufficient materials for 1,464 array sample ... Membrane: 4 each , Blocker BSA in PBS (10X): ... BupH Phosphate Buffered Saline: 8 packs , 10% Tween-20: ... Luminol Enhancer: 2 x 25 ml , SuperSignal West ...
... 100-120 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...
Biology Products: